Sucampo Pharmaceuticals Inc (SCMP.OQ) People | Reuters.com
Edition:
United States

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

10.97USD
30 Jun 2016
Change (% chg)

$0.12 (+1.11%)
Prev Close
$10.85
Open
$10.93
Day's High
$10.99
Day's Low
$10.66
Volume
132,935
Avg. Vol
215,273
52-wk High
$29.62
52-wk Low
$9.61

Summary

Name Age Since Current Position

Peter Greenleaf

45 2016 Chairman of the Board, Chief Executive Officer

Andrew Smith

52 2015 Chief Financial Officer

Max Donley

46 2014 Executive Vice President of Human Resources

Thomas Knapp

62 2012 Executive Vice President, Chief Legal Officer and Corporate Secretary

Matthias Alder

50 2014 Executive Vice President - Business Development & Licensing

Stanley Miele

51 2009 Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC

Peter Kiener

62 2014 Chief Scientific Officer

Peter Lichtlen

47 2014 Chief Medical Officer

John Johnson

57 2016 Lead Independent Director

Daniel Getman

59 2016 Director

Timothy Walbert

48 2015 Director

Barbara Munder

69 2013 Independent Director

Maureen O'Connell

53 2013 Independent Director

Robert Spiegel

65 2015 Independent Director

Silvia Taylor

2014 Senior Vice President - Investor Relations and Corporate Communications

Biographies

Name Description

Peter Greenleaf

Mr. Peter Greenleaf has been appointed as Chairman of the Board, Chief Executive Officer of the Company. He was Director of the Sucampo Pharmaceuticals Inc. Prior to his leadership of Sucampo, Mr. Greenleaf was CEO and Board member of Histogenics Corporation, a regenerative medicine company, from June 2013 through February 2014. From 2008 to June 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. While at MedImmune, Mr. Greenleaf was instrumental in driving the expansion of MedImmune’s pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. Mr. Greenleaf has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and prior to that Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the board of directors of the Biotechnology Industry Organization (BIO), where he also serves on the Governing Board of the Emerging Companies Section. He received a Master of Business Administration degree from St. Joseph’s University and a Bachelor of Science degree from Western Connecticut State University. Our board of directors believes the characteristics that qualify Mr. Greenleaf for service on our board of directors include his leadership experience and extensive commercialization, strategic planning, and drug development experience in the biopharmaceutical industry.

Andrew Smith

Mr. Andrew P. Smith, FCMA, CGMA. is Chief Financial Officer of Company. Mr. Smith joined in February 2011 as Principal Accounting Officer of Sucampo Pharmaceuticals, Inc. and Director, Finance of Sucampo Pharma Europe, Ltd. In January 2012, he was promoted to Vice President, Operations & Finance of Sucampo AG, and in January 2015 he was promoted to Chief Financial Officer. From June 2009 to February 2011, Mr. Smith provided consulting services on financial and accounting matters to Sucampo Pharma Europe, Ltd. From 2006 to 2009, Mr. Smith was Finance Director and Company Secretary of Retroscreen Virology, of London, England, Europe's leading contract virology research organization offering both clinical and analytical services. From 2004 to 2006, he was the Finance Director and Company Secretary-Europe at Clearlab, a division of 1-800 Contacts Inc. following Clearlab's 2004 acquisition of VisionTec CL Ltd., of which he was a co-founder and member of its Board of Directors. Prior to that, Mr. Smith held finance and accounting leadership positions at Biocompatibles, plc., Hydron Ltd., and Allergan Inc.'s UK-based subsidiary. Mr. Smith is a Chartered Global Management Accountant and a Fellow of the Chartered Institute of Management Accountants.

Max Donley

Mr. Max Donley is Executive Vice President of Human Resources of the company since June 2014. Prior to joining Sucampo, Mr. Donley was the Executive Vice President of Human Resources and Corporate Affairs for MedImmune LLC, the global biologics arm of AstraZeneca, where he worked from 2000 to 2013. He served as the Director of Human Resources and Development at Bed, Bath, & Beyond from 1993 to 2000. This work helped build the human resources infrastructure that grew the company from 20 locations in 12 states to 254 locations in 39 states with revenues of $1.8B. Mr. Donley started his career at Fairfield Resources, where he worked from 1992 to 1993, and R.H. Macy & Co. Inc., where he worked from 1991 to 1992. Mr. Donley co-founded Axcelerant Health, a healthcare technology accelerator firm, where he remains a member of the Board of Directors. Mr. Donley earned a bachelor’s degree in general studies from the University of Michigan, and a master’s degree in business administration from George Mason University.

Thomas Knapp

Mr. Thomas J. Knapp is Executive Vice President, Chief Legal Officer and Corporate Secretary of Sucampo Pharmaceuticals, Inc., since March 2012. Mr. Knapp joined company in February 2010 as Senior Vice President, General Counsel and Corporate Secretary. Prior to joining the company, Mr. Knapp was of counsel at Exemplar Law Partners, LLC, and a partner and member at Knapp Law Firm beginning in 2008. From 2003 to 2008, he was Deputy General Counsel and then Vice President, General Counsel and Corporate Secretary at NorthWestern Corporation, an electric and natural gas transmission and distribution company. Mr. Knapp served as of counsel at Paul Hastings LLP, a leading international law firm based in Washington, D.C., from 2001 to 2002. Previously in his career, Mr. Knapp was Assistant General Counsel at The Boeing Company from 1998 to 2000 and served as of counsel at Paul Hastings LLP, from 1996 to 1998. He held various in-house positions, including as Labor Counsel, at The Burlington Northern & Santa Fe Railway Company from 1980 to 1995. Mr. Knapp earned a bachelor’s degree in political science at University of Illinois-Urbana and a juris doctorate at Loyola University of Chicago School of Law.

Matthias Alder

Mr. Matthias Alder, LL.M. is Executive Vice President - Business Development & Licensing of the Company, since October 27, 2014. Prior to joining Sucampo, he served from 2013 to October 2014 as Executive Vice President of Corporate Development and Legal Affairs and Corporate Secretary at Cytos Biotechnology AG, a biopharmaceutical company focused on the development of targeted immunotherapies. From 2006 to 2012 he held various roles of increasing responsibility, including Senior Vice President Administration, General Counsel and Secretary; Legal Affairs, Corporate Secretary and Compliance Officer; and Manager of Human Resources, Quality Assurance, Drug Safety and Intellectual Property at Micromet Inc., which was acquired by Amgen. Mr. Alder was also a partner in the Life Sciences Transactions Practice at Cooley LLP from 1997 to 2006, where he represented biotech companies in strategic transactions with pharmaceutical companies. Earlier in his career, Mr. Alder was in-house counsel at Ciba-Geigy and Novartis from 1994 to 1997. Mr. Alder earned law degrees from the University of Basel and the University of Miami and is qualified to practice law in Switzerland and the U.S.

Stanley Miele

Mr. Stanley G. Miele is Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC., a subsidiary of Sucampo Pharmaceuticals Inc. Mr. Miele became our Senior Vice President of Sales and Marketing in October 2008, promoted from his prior positions as Vice President of Sales and National Director of Sales; he has been with the company since 2006. He was also named President of Sucampo Pharma Americas, LLC in September 2009. Prior to joining Sucampo, Mr. Miele was the i-STAT Executive Sales Manager from 2005 to 2006 for Abbott Diagnostics, a division of global healthcare company Abbott Laboratories. He also held a series of positions at Millennium Pharmaceuticals, where he worked from 2003 to 2005, and at COR Therapeutics, prior to its acquisition by Millennium, including National Sales Director, Cardiology. Mr. Miele started his career as a sales representative both at the Hospital Products Division of Abbott Laboratories, and at Syntex Labs. He earned a bachelor’s degree in management communications from the University of Dayton.

Peter Kiener

Dr. Peter A. Kiener is Chief Scientific Officer of the Company, since October 27, 2014. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates, since 2013. From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener worked on biologics for Bristol-Myers Squibb from 1983 to 2001. He started his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener has served on the scientific advisory Boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener has also served as a director of Receptor BioLogix Inc., Synovex Corporation and Virdante Pharmaceuticals Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. He earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.

Peter Lichtlen

Dr. Peter Lichtlen, M.D., Ph.D. is the Chief Medical Officer of the company since July 2014. Chief Medical Officer of the company since July 2014. He also served as Sucampo’s Senior Medical Officer & Vice President of European Operations from 2011 to 2013. Prior to his appointment as CMO, Dr. Lichtlen was a consultant, providing support to the company in areas such as clinical development, reviews of protocols, the NICE endorsement for AMITIZA® in the U.K., European Medical Affairs activities, as well as medical support for the lubiprostone pediatric functional constipation program. Prior to joining the company, Dr. Lichtlen held various roles at ESBATech AG (acquired by Alcon/Novartis in 2009), of Schlieren, Switzerland, where he worked since 2000. He held several progressively more senior positions, culminating in being named Medical Director/Head, Clinical Research & Development, and a member of its senior management team, a position he held from 2004 to 2010. In that role, he was responsible for setting and managing clinical development strategy; serving as the scientific and medical lead for its clinical programs; overseeing interactions with regulatory agencies in Europe; and identifying new molecular targets and clinical indications, among other duties. Dr. Lichtlen also co-founded Numab AG, a Swiss biotechnology company that innovates antibody-based therapeutics, where he remains a member of the Board of Directors. He is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of four patents. Dr. Lichtlen earned doctorate degrees in medicine and molecular biology at the University of Zurich.

John Johnson

Mr. John H. Johnson is Lead Independent Director of the Company. He was Independent Director of Company. He served as the President and Chief Executive Officer of Dendreon Corporation, a biotechnology company focused on cancer, from 2012 to July 2014. Prior to that, Mr. Johnson served as the Chief Executive Officer of Savient Pharmaceuticals, Inc. from 2011 to 2012, as President of Eli Lilly & Company’s Oncology Unit following its 2008 acquisition of Imclone Systems, Inc., and he held various executive roles of increasing responsibility at Johnson & Johnson, where he worked from 1988 to 2007. Mr. Johnson is currently the chairman of the Board of Directors of Cortendo AB, a global biopharmaceutical company focused on orphan endocrine disorders. He also serves on the Board of Directors of Cempra Inc., a clinical-stage pharmaceutical company, Portola Pharmaceuticals, Inc., a biopharmaceutical company, and Histogenics Corporation, a regenerative medicine company. Previously, he served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO). Mr. Johnson earned a bachelor’s degree from East Stroudsburg University of Pennsylvania.

Daniel Getman

Dr. Daniel P. Getma, Ph.D., is Director of the Company. He an Independent Chairman of the Board of Sucampo Pharmaceuticals, Inc., since March 3, 2014. Dr. Getman has been a Director for Sucampo since September 2011. He served as the President of Kansas City Area Life Sciences, Inc. (KCALSI) from 2009 until his retirement in July 2012. Dr. Getman joined KCALSI from Pfizer, Inc., where he had been Vice President of Global Research and Development and Director of Pfizer’s St. Louis laboratories from 2003 to 2008; Dr. Getman also served on Pfizer’s external research network committee, responsible for the Midwest region. Prior to joining Pfizer, Dr. Getman worked at Pharmacia Corporation, which merged with Pfizer in 2003, and G.D. Searle & Company and Monsanto Company. Dr. Getman’s own research experience spans medicinal chemistry in the areas of arthritis, cancer and infectious diseases, including a large program with G.D. Searle/Monsanto Pharmacia, before its merger with PharmaciaPfizer, on HIV Protease Inhibitors for AIDS that led to three separate licensing deals and two marketed products for AIDS patients – Lexiva® and Prezista®. He also serves as a member of the National Council for the Washington University School of Medicine, is a member of the Board of Managers for the Children’s Discovery Institute at Children’s Hospital/Washington University School of Medicine, and is an advisor to the Wisconsin Alumni Research Foundation catalyst accelerator program. He is currently Board Chair for the Missouri Biotechnology Association and a Board member of the Kansas Bioscience Organization. Dr. Getman earned a bachelor’s degree in chemistry from State University New York Buffalo and a doctorate in organic chemistry from the University of Minnesota.

Timothy Walbert

Mr. Timothy P. Walbert is Director of Sucampo Pharmaceuticals, Inc. Mr. Walbert joined Horizon in June 2008 as President and Chief Executive Officer and has served as Chairman of the Board of Directors since 2010. Prior to joining Horizon, Mr. Walbert served as President, Chief Executive Officer and Director of IDM Pharma, Inc., which was acquired by Takeda in June 2009. Prior to IDM, Mr. Walbert served as Executive Vice President, Commercial Operations at NeoPharm, Inc. From 2001 to 2005, Mr. Walbert served as Divisional Vice President and General Manager, Immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and as Divisional Vice President, Global Cardiovascular Strategy at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as Director, CELEBREX North America and Arthritis Team Leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College. Mr. Walbert serves as Chairman of the Board of Egalet Corporation and sits on the Board of Directors of XOMA Corporation, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council.

Barbara Munder

Ms. Barbara A. Munder is an Independent Director of Sucampo Pharmaceuticals, Inc., since February 27, 2013. Since 2005, Ms. Munder serves as Senior Advisor at Institutional Investor LLC, an international business-to-business publisher. From 2001 to 2005, she was Executive Director of the Institutional Investor Institute and The Hedge Fund Institutional Forum, Institutional Investor LLC. From 2001 to 2002, she was a principal of Munder & Associates, a marketing- and web-strategy consulting firm. Also in 2001, Ms. Munder served as Chief Operating Officer at Womenfuture LLC, a distance learning company, where she oversaw e-business strategy. From 1994 to 2000, Ms. Munder held various positions with The McGraw-Hill Companies, Inc., including Senior Vice President, New Initiatives, with oversight for corporate-wide electronic commerce, and Senior Vice President, Corporate Affairs, with responsibility for branding, marketing, communications, and Washington affairs. Ms. Munder also served as a director of PetSmart Inc. and serves as a director of Munder Realty Corporation, a private real estate firm. Additionally, she has been on the advisory board for DOAR, a private litigation information services and consulting firm; Izzo Systems, a manufacturer of ergonomically designed golf bags and straps; and Lighthouse International, a non-profit for the visually impaired. Ms. Munder holds a B.A. in political science from Elmira College and a M.B.A. in Finance from New York University, Stern School of Business Administration.

Maureen O'Connell

Ms. Maureen E. O'Connell is an Independent Director of Sucampo Pharmaceuticals, Inc., since February 27, 2013. Since 2007, Ms. O’Connell has been the Executive Vice President, Chief Administrative Officer and Chief Financial Officer at Scholastic Inc. Ms. O’Connell has overall responsibility for finance, human resources, information technology, customer service, facilities, supply chain, and manufacturing. From 2005 to 2006, she served as Executive Vice President and Chief Financial Officer at Affinion Group, Inc., a leading affinity direct marketer of membership, insurance and loyalty programs. From 2002 to 2004, she held a series of progressively more responsible positions, including President and Chief Operating Officer and Executive Vice President, Chief Financial and Administrative Officer at Gartner, Inc., a leading technology research and advisory firm. From 2000 to 2002, she worked at Barnes & Noble, as their Executive Vice President and Chief Financial Officer. From 1998 to 2000, she was the Chief Financial Officer and Vice President at Publishers Clearing House. She worked as the Senior Vice President of Finance and Marketing Analysis at BMG Direct from 1997 to 1998. From 1990 to 1997, she held a series of positions at Primedia, Inc., most recently as Chief Financial Officer and Senior Vice President. Ms. O’Connell is a former member of the board of directors of Beazer Homes from 2002 to 2007, where she served as audit chair for most of her tenure. Ms. O’Connell holds a B.S. in Accounting and Economics from New York University, Stern School of Business Administration and is a Certified Public Accountant in the State of New York. Our board of directors believes the characteristics that qualify Ms. O’Connell for service on our board of directors include her senior leadership experience in finance and operations, including in particular her previous experience as a chief financial officer for seven companies.

Robert Spiegel

Robert J. Spiegel, M.D., FACP is Independent Director of Company. Dr. Spiegel was Chief Medical Officer of Schering-Plough and was involved in the successful filing of over 30 New Drug Applications. He also served on the executive committees overseeing research projects and drug licensing activities. Dr. Spiegel joined Schering-Plough in 1983 as Director, Clinical Research, progressing through clinical operations as Vice President of Clinical Research, Senior Vice President of Worldwide Clinical Research and then becoming Chief Medical Officer in 1998. He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania. He is currently an Associate Professor at Weill Cornell Medical Center and serves on the board of directors and scientific advisory committees of a number of companies. Dr. Spiegel also currently serves as Chief Medical Officer at PTC Therapeutics.

Silvia Taylor

Ms. Silvia Taylor is Senior Vice President - Investor Relations and Corporate Communications of Sucampo Pharmaceuticals, Inc. She brings 20 years of marketing and communications experience to Sucampo, including five years in public and media relations and 13 years in biopharmaceutical brand marketing at MedImmune and Pfizer Inc. She has experience in marketing, strategy, new product launches, social media, direct-to-consumer advertising, communications, and public health, and has held leadership roles for Viagra, Exubera, motavizumab, Synagis and FluMist as well as other pre-launch products. Ms. Taylor joins Sucampo from MedImmune where she held positions of increasing responsibility, among them Senior Director of Marketing, RSV Franchise and Senior Director of Marketing, Global Influenza Franchise. Prior to MedImmune, Ms. Taylor worked at Pfizer from 1999 to 2007, where she worked on Viagra and Exubera and in the company's consumer marketing department on patient-directed communications. Ms. Taylor's work has won numerous marketing and pharmaceutical industry awards. She graduated from the University of Virginia with a B.A. in Foreign Affairs and from Columbia Business School where she earned an MBA in Marketing and Management.

Basic Compensation